# Anne M. Wallace

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anne-m-wallace/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,264 |
| Field | Breast Cancer Treatment Studies |
| h-index | 41 |
| i10-index | 113 |
| Last Known Institution | University of California San Diego |
| OpenAlex ID | https://openalex.org/A5090318660 |
| ORCID iD | 0000-0003-2919-2491 |
| Works | 257 |

## Researcher papers

- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Pain after breast surgery: a survey of 282 women](https://scholariq.org/papers/pain-after-breast-surgery-a-survey-of-282-women/)
- [w4200350191](https://scholariq.org/papers/w4200350191/)
- [Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial](https://scholariq.org/papers/durvalumab-with-olaparib-and-paclitaxel-for-high-risk-her2-negative-stage-ii-iii/)
- [Positive Surgical Margins in the 10 Most Common Solid Cancers](https://scholariq.org/papers/positive-surgical-margins-in-the-10-most-common-solid-cancers/)
- [Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](https://scholariq.org/papers/association-of-event-free-and-distant-recurrence-free-survival-with-individual/)
- [Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.](https://scholariq.org/papers/pembrolizumab-plus-standard-neoadjuvant-therapy-for-high-risk-breast-cancer-bc/)
- [A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran.](https://scholariq.org/papers/a-synthetic-macromolecule-for-sentinel-node-detection-99m-tc-dtpa-mannosyl/)
- [Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events](https://scholariq.org/papers/insights-from-a-multi-institutional-registry-show-duration-of-endocrine/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [MRI in cancer diagnosis](https://scholariq.org/topics/mri-in-cancer-diagnosis/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [University of California San Diego](https://scholariq.org/institutions/university-of-california-san-diego/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.